Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 May;61(5):429–437. doi: 10.1136/ard.61.5.429

Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries

A Boonen 1, D van der Heijde 1, R Landewe 1, A Spoorenberg 1, H Schouten 1, M Rutten-Van 1, F Guillemin 1, M Dougados 1, H Mielants 1, K de Vlam 1, H van der Tempel 1, S van der Linden 1
PMCID: PMC1754093  PMID: 11959767

Abstract

Objective: To compare work disability, sick leave, and productivity costs due to ankylosing spondylitis (AS) of three European countries.

Methods: 216 patients with AS from the Netherlands, France, and Belgium participated in a two year observational study. Employment and work disability rates at baseline were adjusted for age and sex. Productivity costs were calculated by both the friction cost method and the human capital approach. The adjusted contributions of country to employment, work disability, and having an episode of sick leave were assessed by logistic regression and the contribution of the country to days of sick leave and costs by Cox proportional hazard analysis.

Results: 209 patients completed the two years' follow up with sufficient data for cost analysis. Adjusted employment was 55% in the Netherlands as compared with 72% in both other countries and only in the Netherlands was it lower than expected in the general population. Adjusted work disability was 41%, 23%, and 9% in the Netherlands, France, and Belgium and in all countries was higher than expected in the general population. In those with a paid job, the mean number of days of sick leave per patient per year because of AS was 19 (range 0–130), six (range 0–77), and nine (range 0–60 ) in the Netherlands, France, and Belgium respectively. Applying the friction cost method to those with a paid job resulted in mean costs per patient per year of 1257 euros (range 0–7356), 428 euros (range 0–5979), and 476 euros (range 0–2354) in the Netherlands, France, and Belgium. Applying the human capital approach to the whole group resulted in mean costs per patient per year of 8862 euros (range 0–46 818), 3188 euros (range 0–43 550), and 3609 euros (range 0–34 320) in the three countries, respectively. After adjusting for sociodemographic and disease characteristics, living in the Netherlands, as compared with both other countries, was associated with a higher chance of being work disabled (odds ratio (OR)=3.82; 95% confidence interval (CI) 1.33 to 11.01), but not with the risk of having an episode of sick leave. Similarly, living in the Netherlands contributed independently to the number of days sick leave (OR=0.65; 95% CI 0.43 to 0.97), a higher amount of friction costs (OR=0.63; 95% CI 0.42 to 0.96), and a higher amount of human capital costs (OR=0.46; 95% CI 0.32 to 0.68).

Conclusion: There are remarkable differences in work status and productivity costs between the three European countries. This has implications for the generalisability of health economic studies.

Full Text

The Full Text of this article is available as a PDF (194.6 KB).

Figure 1 .

Figure 1

Open in a new tab

Kaplan-Meier curve of patients with AS with a paid job, illustrating the proportion of patients incurring a specific level of friction costs in each country separately.

Figure 2 .

Figure 2

Open in a new tab

Kaplan-Meier curve of the active working population, illustrating the proportion of patients with AS incurring a specific level of human capital costs in each country separately.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boonen A., Chorus A., Miedema H., van der Heijde D., van der Tempel H., van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis. 2001 Apr;60(4):353–358. doi: 10.1136/ard.60.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58–67. doi: 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  3. Calin A., Garrett S., Whitelock H., Kennedy L. G., O'Hea J., Mallorie P., Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281–2285. [PubMed] [Google Scholar]
  4. Clarke A. E., Petri M. A., Manzi S., Isenberg D. A., Gordon C., Senecal J. L., St Pierre Y., Joseph L., Penrod J., Fortin P. R. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol. 1999 Jul;26(7):1500–1511. [PubMed] [Google Scholar]
  5. Clarke A. E., Zowall H., Levinton C., Assimakopoulos H., Sibley J. T., Haga M., Shiroky J., Neville C., Lubeck D. P., Grover S. A. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol. 1997 Jun;24(6):1051–1060. [PubMed] [Google Scholar]
  6. Cooper N. J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000 Jan;39(1):28–33. doi: 10.1093/rheumatology/39.1.28. [DOI] [PubMed] [Google Scholar]
  7. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997 Nov;35(11):1095–1108. doi: 10.1097/00005650-199711000-00002. [DOI] [PubMed] [Google Scholar]
  8. Gabriel S. E., Crowson C. S., Campion M. E., O'Fallon W. M. Direct medical costs unique to people with arthritis. J Rheumatol. 1997 Apr;24(4):719–725. [PubMed] [Google Scholar]
  9. Gabriel S. E., Crowson C. S., Campion M. E., O'Fallon W. M. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol. 1997 Jan;24(1):43–48. [PubMed] [Google Scholar]
  10. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–2291. [PubMed] [Google Scholar]
  11. Gran J. T., Husby G. Ankylosing spondylitis: a comparative study of patients in an epidemiological survey, and those admitted to a department of rheumatology. J Rheumatol. 1984 Dec;11(6):788–793. [PubMed] [Google Scholar]
  12. Jonsson B., Rehnberg C., Borgquist L., Larsson S. E. Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand. 1992 Apr;63(2):207–212. doi: 10.3109/17453679209154825. [DOI] [PubMed] [Google Scholar]
  13. Jonsson D., Husberg M. Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Health Care. 2000 Autumn;16(4):1193–1200. doi: 10.1017/s0266462300103228. [DOI] [PubMed] [Google Scholar]
  14. Koopmanschap M. A., Rutten F. F. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996 Nov;10(5):460–466. doi: 10.2165/00019053-199610050-00003. [DOI] [PubMed] [Google Scholar]
  15. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol. 1996 Aug;35(8):781–790. doi: 10.1093/rheumatology/35.8.781. [DOI] [PubMed] [Google Scholar]
  16. Meenan R. F., Yelin E. H., Henke C. J., Curtis D. L., Epstein W. V. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum. 1978 Sep-Oct;21(7):827–833. doi: 10.1002/art.1780210714. [DOI] [PubMed] [Google Scholar]
  17. Merkesdal S., Ruof J., Schöffski O., Bernitt K., Zeidler H., Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 2001 Mar;44(3):528–534. doi: 10.1002/1529-0131(200103)44:3<528::AID-ANR100>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  18. Miedema H. S., van der Linden S. M., Rasker J. J., Valkenburg H. A. National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. Br J Rheumatol. 1998 May;37(5):555–561. doi: 10.1093/rheumatology/37.5.555. [DOI] [PubMed] [Google Scholar]
  19. Newhall-Perry K., Law N. J., Ramos B., Sterz M., Wong W. K., Bulpitt K. J., Park G., Lee M., Clements P., Paulus H. E. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol. 2000 May;27(5):1156–1163. [PubMed] [Google Scholar]
  20. Sailly J. C., Lebrun T. Les conséquences économiques et sociales de la pelvispondylite rhumatismale. Rev Epidemiol Sante Publique. 1982;30(3):305–324. [PubMed] [Google Scholar]
  21. Severens J. L., Mulder J., Laheij R. J., Verbeek A. L. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med. 2000 Jul;51(2):243–249. doi: 10.1016/s0277-9536(99)00452-9. [DOI] [PubMed] [Google Scholar]
  22. Sutcliffe N., Clarke A. E., Taylor R., Frost C., Isenberg D. A. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001 Jan;40(1):37–47. doi: 10.1093/rheumatology/40.1.37. [DOI] [PubMed] [Google Scholar]
  23. Thompson S. G., Barber J. A. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000 Apr 29;320(7243):1197–1200. doi: 10.1136/bmj.320.7243.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Yelin E., Herrndorf A., Trupin L., Sonneborn D. A national study of medical care expenditures for musculoskeletal conditions: the impact of health insurance and managed care. Arthritis Rheum. 2001 May;44(5):1160–1169. doi: 10.1002/1529-0131(200105)44:5<1160::AID-ANR199>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  25. Zink A., Braun J., Listing J., Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000 Mar;27(3):613–622. [PubMed] [Google Scholar]
  26. van Roijen L., Koopmanschap M. A., Rutten F. F., van der Maas P. J. Indirect costs of disease; an international comparison. Health Policy. 1995 Jul;33(1):15–29. doi: 10.1016/0168-8510(94)00704-i. [DOI] [PubMed] [Google Scholar]
  27. van Tulder M. W., Koes B. W., Bouter L. M. A cost-of-illness study of back pain in The Netherlands. Pain. 1995 Aug;62(2):233–240. doi: 10.1016/0304-3959(94)00272-G. [DOI] [PubMed] [Google Scholar]
  28. van der Linden S. M., Valkenburg H. A., de Jongh B. M., Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984 Mar;27(3):241–249. doi: 10.1002/art.1780270301. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES